Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 4
2005 3
2006 3
2007 11
2008 7
2009 12
2010 5
2011 14
2012 15
2013 17
2014 19
2015 23
2016 20
2017 20
2018 24
2019 19
2020 25
2021 23
2022 20
2023 26
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

274 results

Results by year

Filters applied: . Clear all
Page 1
Early Metabolic Endpoints Identify Persistent Treatment Efficacy in Recent-Onset Type 1 Diabetes Immunotherapy Trials.
Jacobsen LM, Cuthbertson D, Bundy BN, Atkinson MA, Moore W, Haller MJ, Russell WE, Gitelman SE, Herold KC, Redondo MJ, Sims EK, Wherrett DK, Moran A, Pugliese A, Gottlieb PA, Sosenko JM, Ismail HM; Type 1 Diabetes TrialNet Study Group. Jacobsen LM, et al. Among authors: haller mj. Diabetes Care. 2024 Apr 15:dc240171. doi: 10.2337/dc24-0171. Online ahead of print. Diabetes Care. 2024. PMID: 38621411
COVID-19 impacts and inequities among underserved communities with diabetes.
Maizel JL, Haller MJ, Maahs DM, Addala A, Lal RA, Filipp SL, Gurka MJ, Westen S, Dixon BN, Figg L, Hechavarria M, Malden KG, Walker AF. Maizel JL, et al. Among authors: haller mj. J Clin Transl Endocrinol. 2024 Mar 19;36:100337. doi: 10.1016/j.jcte.2024.100337. eCollection 2024 Jun. J Clin Transl Endocrinol. 2024. PMID: 38559803 Free PMC article.
Intake of B vitamins and the risk of developing islet autoimmunity and type 1 diabetes in the TEDDY study.
Hakola L, Mramba LK, Uusitalo U, Andrén Aronsson C, Hummel S, Niinistö S, Erlund I, Yang J, Rewers MJ, Akolkar B, McIndoe RA, Rich SS, Hagopian WA, Ziegler A, Lernmark Å, Toppari J, Krischer JP, Norris JM, Virtanen SM; TEDDY Study Group. Hakola L, et al. Eur J Nutr. 2024 Feb 27. doi: 10.1007/s00394-024-03346-6. Online ahead of print. Eur J Nutr. 2024. PMID: 38413484
C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis.
Taylor PN, Collins KS, Lam A, Karpen SR, Greeno B, Walker F, Lozano A, Atabakhsh E, Ahmed ST, Marinac M, Latres E, Senior PA, Rigby M, Gottlieb PA, Dayan CM; Trial Outcome Markers Initiative collaboration. Taylor PN, et al. Lancet Diabetes Endocrinol. 2023 Dec;11(12):915-925. doi: 10.1016/S2213-8587(23)00267-X. Epub 2023 Nov 3. Lancet Diabetes Endocrinol. 2023. PMID: 37931637 Free article.
Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes.
Ramos EL, Dayan CM, Chatenoud L, Sumnik Z, Simmons KM, Szypowska A, Gitelman SE, Knecht LA, Niemoeller E, Tian W, Herold KC; PROTECT Study Investigators. Ramos EL, et al. N Engl J Med. 2023 Dec 7;389(23):2151-2161. doi: 10.1056/NEJMoa2308743. Epub 2023 Oct 18. N Engl J Med. 2023. PMID: 37861217 Clinical Trial.
274 results